DGAP-News: ABDELGHANI OMARI APPOINTED AS NEW CHIEF FINANCIAL OFFICER AT PAION AG

        Print
| Source: EQS Group AG
DGAP-News: PAION AG / Key word(s): Change of Personnel
ABDELGHANI OMARI APPOINTED AS NEW CHIEF FINANCIAL OFFICER AT PAION AG

27.08.2014 / 10:10

---------------------------------------------------------------------

ABDELGHANI OMARI APPOINTED AS NEW CHIEF FINANCIAL OFFICER AT PAION AG

Aachen (Germany), 27 August 2014 - PAION AG, a Specialty Pharma Company
(ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces
that Abdelghani Omari (37) has been appointed by the Supervisory Board as a
new member of the Management Board of PAION AG and is Chief Financial
Officer with effect from 1 September 2014.

Abdelghani Omari has been with PAION as Vice President Finance since
October 2008 and after the departure of Bernhard Hofer as CFO in early 2012
he has taken over his duties but reporting to the  management board. Mr
Omari has intensively worked on the restructuring process and the
repositioning of PAION AG in the last years and was responsible and
involved in various capital market transactions and licensing agreements as
Vice President Finance.

Prior to joining PAION AG, Abdelghani Omari held various positions at KPMG,
Cologne in auditing and advisory. He studied at the University of Aachen
and has a Diploma in Business Administration.

"I am delighted to win an experienced financial expert from among our ranks
to the position of CFO. Mr. Omari has excellent knowledge of PAION's
business model and will accompany the company in an even stronger position
on the path through the Phase III program up to approval and
commercialization. I wish him continued success in his new function," says
Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG.

"Since 2012, we have jointly conducted a total of seven product-related
transactions and three financial market transactions. Mr Omari's
entrepreneurial determination combined with the sensitivity for the
respective financial risks has contributed significantly to the current
position of PAION," commented Dr. Wolfgang Söhngen, CEO of PAION.

###

About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany with a second site in Cambridge, UK. The company has a
track record in developing hospital-based treatments for which there is
substantial unmet medical need. PAION's strategy is to extend its business
model from a pure development company to a specialty pharmaceutical company
with a focus on anaesthesia products.  Remimazolam is intended to be the
basis for its future marketing activities.

PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com 

Disclaimer:

This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.



---------------------------------------------------------------------

27.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                               
Company:     PAION AG                                              
             Martinstr. 10-12                                      
             52062 Aachen                                          
             Germany                                               
Phone:       +49 (0)241-4453-0                                     
Fax:         +49 (0)241-4453-100                                   
E-mail:      info@paion.com                                        
Internet:    www.paion.com                                         
ISIN:        DE000A0B65S3                                          
WKN:         A0B65S                                                
Listed:      Regulierter Markt in Frankfurt (Prime Standard);      
             Freiverkehr in Berlin, Düsseldorf, Hamburg, München,  
             Stuttgart                                             
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
283966 27.08.2014